- Destination XL, a plus-size men's clothing chain, reported a 6% decrease in sales for the fourth quarter of its 2025 fiscal year, totaling $112.1 million.
- DXL's CEO, Harvey Kanter, said GLP-1 weight-loss drugs are impacting the business more than initially expected, contributing to the sales decline.
- Kanter suggested that customers on weight-loss journeys are delaying clothing purchases until they reach their desired weight, leading to market volatility.
- A recent poll indicated that 1 in 8 US adults are currently taking a GLP-1 drug, with common reasons for discontinuation including financial issues, side effects, and drug shortages.
- Despite the sales dip, DXL is optimistic for the upcoming fiscal year and plans to merge with FullBeauty Brands in the second quarter of 2026, anticipating significant revenue and cost synergies.
IN FULL
